Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity

Cited by (576)

Items 101–200 of 576

1. Fibroblast growth factor-21, energy balance and obesity
   Marta Giralt, Aleix Gavaldà‐Navarro, Francesc Villarroya · 2015 · Molecular and Cellular Endocrinology
2. Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism
   Eric K. Kwong, Yunzhou Li, Phillip B. Hylemon, Huiping Zhou · 2015 · Acta Pharmaceutica Sinica B
3. Different roles of N‐ and C‐ termini in the functional activity of FGF21
   Micanovic, Radmila, Raches, David W., Dunbar, James D., Driver, David A., Bina, Holly A., Dickinson, Craig D., Kharitonenkov, Alexei · 2009 · Journal of Cellular Physiology
4. Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
   Piero Portincasa, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, György Baffy, Agostino Di Ciaula · 2024 · International Journal of Molecular Sciences
5. The FGF metabolic axis
   Xiaokun Li · 2019 · Frontiers of Medicine
6. Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling
   Wu, Xinle, Ge, Hongfei, Gupte, Jamila, Weiszmann, Jennifer, Shimamoto, Grant, Stevens, Jennitte, Hawkins, Nessa, Lemon, Bryan, Shen, Wenyan, Xu, Jing et al. · 2007 · Journal of Biological Chemistry
7. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review
   Nicholas Charles Penney, James K. Kinross, Richard C. Newton, Sanjay Purkayastha · 2015 · International Journal of Obesity
8. FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
   Xinqiang Huang, Chaofeng Yang, Yongde Luo, C. Jin, Fen Wang, W. Mckeehan · 2007 · Diabetes
9. Fibroblast Growth Factor Signaling in Metabolic Regulation
   Vera J. M. Nies, Gencer Sancar, Weilin Liu, Tim van Zutphen, Dicky Struik, Ruth T. Yu, Annette R. Atkins, Ronald M. Evans, Johan W. Jonker, Michael Downes · 2016 · Frontiers in Endocrinology
10. Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes
    David Peick Sonne, F. Samuel van Nierop, Willem Kulik, Maarten R. Soeters, Tina Vilsbøll, Filip Krag Knop · 2016 · The Journal of Clinical Endocrinology & Metabolism
11. Metabolic Messengers: fibroblast growth factor 15/19
    Raffaella Maria Gadaleta, Antonio Moschetta · 2019 · Nature Metabolism
12. Pathogenesis of NASH: the Impact of Multiple Pathways
    Mazen Noureddin, Arun Jayant Sanyal · 2018 · Current Hepatology Reports
13. FGFs and metabolism
    Alexei Kharitonenkov · 2009 · Current Opinion in Pharmacology
14. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis
    Perry, Rachel J., Lee, Sangwon, Ma, Lie, Zhang, Dongyan, Schlessinger, Joseph, Shulman, Gerald I. · 2015 · Nature Communications
15. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases
    Fangfang Zhang, Lechu Yu, Xiufei Lin, Peng Cheng, Luqing He, Xiaokun Li, Xuemian Lu, Yi Tan, Hong Yang, Lu Cai et al. · 2015 · Molecular Endocrinology
16. Fibroblast growth factor receptors, developmental corruption and malignant disease.
    F. Kelleher, H. O'Sullivan, E. Smyth, R. McDermott, A. Viterbo · 2013 · Carcinogenesis
17. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice
    Mei Zhou, R. Marc Learned, Stephen J. Rossi, Alex M. DePaoli, Hui Tian, Lei Ling · 2015 · Hepatology
18. Roles of FGF19 in Liver Metabolism
    Serkan Kır, Steven A. Kliewer, David J. Mangelsdorf · 2011 · Cold Spring Harbor Symposia on Quantitative Biology
19. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids
    Courtney B. Ferrebee, Paul A. Dawson · 2015 · Acta Pharmaceutica Sinica B
20. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis
    Ewa Wunsch, Jocelyn Trottier, Małgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon Morris Hirschfield, Olivier Barbier, Piotr Milkiewicz · 2014 · Hepatology
21. Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs
    Anthony D. Gagliardi, Evan Y. W. Kuo, Sanda Raulic, Graham F. Wagner, Gabriel E. DiMattia · 2004 · American Journal of Physiology-Endocrinology and Metabolism
22. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
    Zhou, Mei, Yang, Hong, Learned, R. Marc, Tian, Hui, Ling, Lei · 2017 · Nature Communications
23. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs
    Ajay Kumar Jain, Barbara Stoll, Douglas G. Burrin, Jens Juul Holst, David D. Moore · 2011 · American Journal of Physiology-Gastrointestinal and Liver Physiology
24. Mistimed food intake and sleep alters 24-hour time-of-day patterns of the human plasma proteome
    Depner, Christopher M., Melanson, Edward L., McHill, Andrew W., Wright, Kenneth P. · 2018 · Proceedings of the National Academy of Sciences
25. Control of body weight: a physiologic and transgenic perspective
    Gema Frühbeck, Javier Gómez‐Ambrosi · 2003 · Diabetologia
26. Naringenin Prevents Obesity, Hepatic Steatosis, and Glucose Intolerance in Male Mice Independent of Fibroblast Growth Factor 21
    Julia M. Assini, Erin E. Mulvihill, Amy C. Burke, Brian G. Sutherland, Dawn E. Telford, Sanjiv S. Chhoker, Cynthia G. Sawyez, Maria Drangova, Andrew Charles Adams, Alexei Kharitonenkov et al. · 2015 · Endocrinology
27. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF‐19 and FGF‐21 in morbidly obese subjects
    D Haluzíková, Z Lacinová, Petra Kaválková, J. Drápalová, Jarmila Křížová, Markéta Bártlová, Miloš Mráz, Tomáš Petr, Libor Vı́tek, Mojmir Kasalicky et al. · 2013 · Obesity
28. Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
    Emmanuel Somm, François R. Jornayvaz · 2018 · Endocrine Reviews
29. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21
    Eleni M. Domouzoglou, Katerina Κ. Naka, Antonios P. Vlahos, Michail I. Papafaklis, Lampros K. Michalis, Agathoklis Tsatsoulis, Eleftheria Maratos–Flier · 2015 · American Journal of Physiology-Heart and Circulatory Physiology
30. Mini-Review: Endocrine Actions of Fibroblast Growth Factor 19
    Stacey A. Jones · 2008 · Molecular Pharmaceutics
31. FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
    Alexei Kharitonenkov, Richard D. DiMarchi · 2015 · Trends in Endocrinology and Metabolism
32. Farnesoid X receptor: A “homeostat” for hepatic nutrient metabolism
    Vittoria Massafra, Saskia W. C. van Mil · 2017 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
33. Bile Acid Binding Resin Improves Metabolic Control through the Induction of Energy Expenditure
    光博 渡辺, Kohkichi Morimoto, Sander M. Houten, Nao Kaneko-Iwasaki, Taichi Sugizaki, Yasushi Horai, Chikage Mataki, Hiroyuki Sato, Karin Murahashi, Eri Arita et al. · 2012 · PLoS ONE
34. Gut-liver axis signaling in portal hypertension
    Benedikt Simbrunner, Mattias Mandorfer, Michael Trauner, Thomas Reiberger · 2019 · World Journal of Gastroenterology
35. FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes
    Saachi Sachdev, Qi Wang, Charles John Billington, John Connett, Leaque Ahmed, William B. Inabnet, Streamson C. Chua, Sayeed Ikramuddin, Judith Körner · 2015 · Obesity Surgery
36. FGF19 protects skeletal muscle against obesity‐induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT‐1/PGC‐α pathway
    Ai Guo, Kai Li, Hongchuan Tian, Zhen Fan, Qiu‐Nan Chen, Yun‐Fei Yang, Jing Yu, Yong‐Xin Wu, Qian Xiao · 2021 · Journal of Cellular and Molecular Medicine
37. Plasma Concentrations of Fibroblast Growth Factors 19 and 21 in Patients with Anorexia Nervosa
    I Dostálová, Petra Kaválková, D Haluzíková, Z Lacinová, Miloš Mráz, Hana Papežová, Martin Haluzı́k · 2008 · The Journal of Clinical Endocrinology & Metabolism
38. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse
    Elaine M. Quinet, Michael Basso, Anita R. Halpern, David W. Yates, Robert J. Steffan, Valerie M. Clerin, Christine Resmini, James C. Keith, Thomas J. Berrodin, Irene B. Feingold et al. · 2009 · Journal of Lipid Research
39. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19
    Cecilia Gälman, Bo Angelin, Mats J. Rudling · 2011 · Journal of Internal Medicine
40. Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
    Kolumam, Ganesh, Chen, Mark Z., Tong, Raymond, Zavala-Solorio, Jose, Kates, Lance, van Bruggen, Nicholas, Ross, Jed, Wyatt, Shelby K., Gandham, Vineela D., Carano, Richard A.D. et al. · 2015 · EBioMedicine
41. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease
    Yingfei Xi, Hongshan Li · 2019 · Biomedicine & Pharmacotherapy
42. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
    Junichiro Sonoda, Mark Z. Chen, Amos Baruch · 2017 · Hormone Molecular Biology and Clinical Investigation
43. Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery
    Nadejda Bozadjieva-Kramer, Kristy M. Heppner, Randy J. Seeley · 2018 · Diabetes
44. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)
    Xinle Wu, Hongfei Ge, Bryan D. Lemon, Steven L. Vonderfecht, Hélène Baribault, Jennifer Weiszmann, Jamila Gupte, Jonitha Gardner, Richard A. Lindberg, Zhulun Wang et al. · 2010 · Proceedings of the National Academy of Sciences
45. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
    Zhou, Mei, Luo, Jian, Chen, Michael, Yang, Hong, Learned, R. Marc, DePaoli, Alex M., Tian, Hui, Ling, Lei · 2017 · Journal of Hepatology
46. Independent Repression of Bile Acid Synthesis and Activation of c-Jun N-terminal Kinase (JNK) by Activated Hepatocyte Fibroblast Growth Factor Receptor 4 (FGFR4) and Bile Acids
    Chundong Yu, Fen Wang, Chengliu Jin, Xinqiang Huang, Wallace L. McKeehan · 2005 · Journal of Biological Chemistry
47. Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis
    Markan, Kathleen R., Potthoff, Matthew J. · 2016 · Seminars in Cell & Developmental Biology
48. Fibroblast growth factor 21 night watch: advances and uncertainties in the field
    Alexei Kharitonenkov, Richard D. DiMarchi · 2016 · Journal of Internal Medicine
49. Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
    Emina Halilbasic, Anna Baghdasaryan, Michael A Trauner · 2013 · Clinics in Liver Disease
50. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes
    Lihong Chen, Xiaozhou Yao, Andrew Young, Judi A. McNulty, Don Anderson, Yaping Liu, Christopher Nystrom, Dallas K. Croom, Sean A. Ross, Jon L. Collins et al. · 2011 · American Journal of Physiology-Endocrinology and Metabolism
51. FGFR4: A promising therapeutic target for breast cancer and other solid tumors
    Kevin M. Levine, Kai Ding, Lyuqin Chen, Steffi Oesterreich · 2020 · Pharmacology & Therapeutics
52. Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases
    Alexei Kharitonenkov, Armen B. Shanafelt · 2008 · BioDrugs
53. Enhancing hepatic glycolysis reduces obesity: Differential effects on lipogenesis depend on site of glycolytic modulation
    Chaodong Wu, Johnthomas Kang, Li-Jen Peng, Honggui Li, Salmaan Ahmed Khan, Christopher J. Hillard, David Anthony Okar, Alex J. Lange · 2005 · Cell Metabolism
54. Cholecystectomy increases hepatic triglyceride content and very‐low‐density lipoproteins production in mice
    Ludwig Amigo, Constanze Husche, Silvana Zanlungo, Dieter Lütjohann, Marco A. Arrese, Juan Francisco Miquel, Attilio Rigotti, Flavio O. Nervi · 2010 · Liver International
55. Intestinal Flora is a Key Factor in Insulin Resistance and Contributes to the Development of Polycystic Ovary Syndrome
    Yue Yang, Weiwei Zhou, Shangong Wu, Wenli Tang, Zongwei Wang, Zuyi Zhou, Ze-Wen Li, Qing-Fa Huang, Yan He, Hongwei Zhou · 2021 · Endocrinology
56. FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
    Emma Henriksson, Birgitte Andersen · 2020 · Frontiers in Endocrinology
57. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys
    Haijun D. Sun, Maria Malabunga, James R. Tonra, Roberto DiRenzo, Francine E. Carrick, Huiyuan Zheng, Hans‐Rudolf Berthoud, Owen P. McGuinness, Juqun Shen, Peter Böhlen et al. · 2006 · American Journal of Physiology-Endocrinology and Metabolism
58. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver
    Claudia Cicione, Chiara Degirolamo, Antonio Moschetta · 2012 · Hepatology
59. Regulation of Complement C3 Expression by the Bile Acid Receptor FXR
    Jiali Li, Parinaz C. Pircher, Ira G. Schulman, Stefan K. Westin · 2004 · Journal of Biological Chemistry
60. The Structural Biology of the FGF19 Subfamily
    Beenken, Andrew, Mohammadi, Moosa · 2012 · Advances in Experimental Medicine and Biology
61. FGF23-αKlotho as a paradigm for a kidney-bone network
    Makoto Kuro‐o, Orson W. Moe · 2016 · Bone
62. Bile Acid Sequestrants for Lipid and Glucose Control
    Bart Staels, Yehuda Handelsman, Vivian Andrew Fonseca · 2010 · Current Diabetes Reports
63. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes
    Roxanne Dutia, M Embrey, Sinead A. O'Brien, Rebecca A. Haeusler, Keesandra Agenor, Peter Homel, J McGinty, Royce P Vincent, Jamie Alaghband-Zadeh, Bart Staels et al. · 2015 · International Journal of Obesity
64. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice
    Xinle Wu, Hongfei Ge, Bryan D. Lemon, Jennifer Weiszmann, Jamila Gupte, Nessa Hawkins, Xiaofan Li, Jie Tang, Richard A. Lindberg, Yang Li · 2009 · Proceedings of the National Academy of Sciences
65. Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
    Tiangang Li, John Y.L. Chiang · 2020 · HepatoBiliary Surgery and Nutrition
66. C-terminal Tail of FGF19 Determines Its Specificity toward Klotho Co-receptors
    Xinle Wu, Bryan D. Lemon, Xiaofan Li, Jamila Gupte, Jennifer Weiszmann, Jennitte L. Stevens, Nessa Hawkins, Wenyan David Shen, Richard A. Lindberg, Jinlong Chen et al. · 2008 · Journal of Biological Chemistry
67. A Prospective Randomized Controlled Trial of the Metabolic Effects of Sleeve Gastrectomy with Transit Bipartition
    Fernanda Reis de Azevedo, Sérgio Santoro, Maria Lúcia Corrêa‐Giannella, Marcos Tadashi Kakitani Toyoshima, Daniel Giannella‐Neto, Daniela Calderaro, Danielle Menosi Gualandro, Pai Ching Yu, Bruno Caramelli · 2018 · Obesity Surgery
68. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus
    Wing Yan So, Po Sing Leung · 2016 · Medicinal Research Reviews
69. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus
    I Dostálová, D Haluzíková, Martin Haluzı́k · 2009 · Physiological Research
70. Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes
    Gerardo Calderón, ALISON N. MCRAE, Juraj Rievaj, Judith A. Davis, Inuk Zandvakili, Sara Linker Nord, Duane B. Burton, Geoffrey P. Roberts, Frank M. Reimann, Bronislava R. Gedulin et al. · 2020 · EBioMedicine
71. Klotho Coreceptors Inhibit Signaling by Paracrine Fibroblast Growth Factor 8 Subfamily Ligands
    R. Goetz, Mutsuko Ohnishi, Xunshan Ding, H. Kurosu, Lei Wang, J. Akiyoshi, Jing-Hong Ma, Wei-Ming Gai, Y. Sidis, N. Pitteloud et al. · 2012 · Molecular and Cellular Biology
72. Cholecystectomy and risk of metabolic syndrome
    Agostino Di Ciaula, Gabriella Garruti, David Q.‐H. Wang, Piero Portincasa · 2018 · European Journal of Internal Medicine
73. FGF19 and FGF21: In NASH we trust
    Saswata Talukdar, Alexei Kharitonenkov · 2020 · Molecular Metabolism
74. Serum Concentrations of Fibroblast Growth Factor 19 in Patients With Obesity and Type 2 Diabetes Mellitus: the Influence of Acute Hyperinsulinemia, Very-Low Calorie Diet and PPAR-α Agonist Treatment
    Miloš Mráz, Z Lacinová, Petra Kaválková, D Haluzíková, Pavel Trachta, J. Drápalová, Veronika Hanušová, Martin Haluzı́k · 2011 · Physiological Research
75. Bile acid sequestrants: more than simple resins
    Carolien Out, A. K. Groen, G. Brufau · 2012 · Current Opinion in Lipidology
76. Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome.
    Laurence Poekes, N. Lanthier, I. Leclercq · 2015 · Clinical science
77. Developments in bile salt based therapies: A critical overview
    Joanne M. Donkers, Reinout L.P. Roscam Abbing, Stan F.J. van de Graaf · 2018 · Biochemical Pharmacology
78. Role of bile acids in the regulation of the metabolic pathways
    Taoka, Hiroki, Yokoyama, Yoko, Morimoto, Kohkichi, Kitamura, Naho, Tanigaki, Tatsuya, Takashina, Yoko, Tsubota, Kazuo, Watanabe, Mitsuhiro · 2016 · World Journal of Diabetes
79. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma
    Dimitra Repana, Paul J. Ross · 2015 · Diseases
80. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19
    Francisco Barrera M., Lorena Azócar, Héctor Molina, Kurt Alex Schalper, Marcia Ocares, Jéssica Liberona, Luis Antonio Villarroel, Fernando Pimentel, Rosa María Pérez‐Ayuso, Flavio O. Nervi et al. · 2015 · Annals of Hepatology
81. Fibroblast Growth Factor 19 Treatment Ameliorates Disruption of Hepatic Lipid Metabolism in Farnesoid X Receptor (Fxr)-Null Mice
    Miyata, Masaaki, Sakaida, Yumi, Matsuzawa, Hitomi, Yoshinari, Kouichi, Yamazoe, Yasushi · 2011 · Biological and Pharmaceutical Bulletin
82. Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
    Kook Hwan Kim, Myung‐Shik Lee · 2018 · Frontiers in Endocrinology
83. Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
    Tiangang Li, John Y.L. Chiang · 2024 · Pharmacological Reviews
84. MECHANISMS IN ENDOCRINOLOGY: Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion
    David Peick Sonne, Morten Hansen, Filip Krag Knop · 2014 · European Journal of Endocrinology
85. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
    Paul Peter Manka, Amos Cornelius Zeller, Wing‐Kin Syn · 2019 · Drugs
86. Serum Concentrations of Fibroblast Growth Factors 19 and 21 in Women with Gestational Diabetes Mellitus: Association with Insulin Resistance, Adiponectin, and Polycystic Ovary Syndrome History
    Dongyu Wang, Wenjing Zhu, LI Jie-ming, Chongyou An, Zilian Wang · 2013 · PLoS ONE
87. Administration of Ampicillin Elevates Hepatic Primary Bile Acid Synthesis through Suppression of Ileal Fibroblast Growth Factor 15 Expression
    Miyata, Masaaki, Takamatsu, Yuki, Kuribayashi, Hideaki, Yamazoe, Yasushi · 2009 · The Journal of Pharmacology and Experimental Therapeutics
88. The heteromeric organic solute transporter, OSTα–OSTβ/SLC51: A transporter for steroid-derived molecules
    Nazzareno Ballatori, Whitney V. Christian, Sadie G. Wheeler, Christine L. Hammond · 2013 · Molecular Aspects of Medicine
89. Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications
    Jin, Leigang, Yang, Ranyao, Geng, Leiluo, Xu, Aimin · 2023 · Annual Review of Pharmacology and Toxicology
90. Dual actions of fibroblast growth factor 19 on lipid metabolism
    Xinle Wu, Hongfei Ge, Hélène Baribault, Jamila Gupte, Jennifer Weiszmann, Bryan D. Lemon, Jonitha Gardner, Preston Fordstrom, Jie Tang, Mingyue Zhou et al. · 2012 · Journal of Lipid Research
91. An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity
    Nasim Babaknejad, Hashem Nayeri, Roohullah Hemmati, Somaye Bahrami, Ahmad Esmaillzadeh · 2018 · Hormone and Metabolic Research
92. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
    Shipeng Zhou, Huimin You, Shuting Qiu, Dawei Yu, Yan Bai, Jincan He, Hua Cao, Qishi Che, Jiao Guo, Zhengquan Su · 2022 · Biomedicine & Pharmacotherapy
93. The relationship between postprandial bile acid concentration, GLP‐1, PYY and ghrelin
    Rachel E. Roberts, C. Glicksman, Jamie Alaghband-Zadeh, Roy A Sherwood, N. Akuji, Carel Wynand le Roux · 2010 · Clinical Endocrinology
94. Physiological Functions and Underlying Mechanisms of Fibroblast Growth Factor (FGF) Family Members: Recent Findings and Implications for Their Pharmacological Application
    Toru Imamura · 2014 · Biological and Pharmaceutical Bulletin
95. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling
    Agostino Di Ciaula, Leonilde Bonfrate, Jacek Baj, Mohamad Khalil, Gabriella Garruti, Frans Stellaard, Helen H. Wang, David Q.‐H. Wang, Piero Portincasa · 2022 · Nutrients
96. Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease.
    D. Burrin, K. Ng, B. Stoll, M. S. de Pipaon · 2014 · Advances in Nutrition
97. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques
    So-Yeon An, Min Suk Lee, Sang‐A Yi, Eun Suk Ha, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Kwan Woo Lee · 2012 · Diabetes Research and Clinical Practice
98. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome.
    Burcu Barutçuoğlu, Güneş Başol, Yasemin Çakır, Şevki Çetinkalp, Zuhal Parıldar, Ceyda Kabaroğlu, Dilek Ozmen, Isil MUTAF, Oya Bayındır · 2011 · PubMed
99. Physiology of FGF15/19
    Stacey A. Jones · 2012 · Advances in experimental medicine and biology
100. The Role of Fibroblast Growth Factor 21 (FGF21) on Energy Balance, Glucose and Lipid Metabolism
     Daniel Cuevas Ramos, Paloma Almeda‐Valdés, Carlos Alberto Aguilar-Salinas, Gabriel Cuevas-Ramos, Andres Cuevas-Sosa, Francisco Javier Gomez-Perez · 2009 · Current Diabetes Reviews